氟尿嘧啶植入剂对进展期胃癌患者腹腔化疗安全性的考察Δ
x

请在关注微信后,向客服人员索取文件

篇名: 氟尿嘧啶植入剂对进展期胃癌患者腹腔化疗安全性的考察Δ
TITLE:
摘要: 目的:探讨氟尿嘧啶植入剂对进展期胃癌患者腹腔化疗安全性的影响。 方法:回顾性分析264例进展期胃癌患者资料。所有患者均术中给予氟尿嘧啶植入剂800 mg,分散放入肠系膜根部及手术区域,每个植入点给药量≤200 mg,且植入范围距切口及吻合口距离需保持>3 cm。术前30 min、术中3 h时,术后1~3 d常规应用第二代头孢菌素。观察所有患者术后住院期间的并发症及不良反应发生情况。结果:共有6例患者术后出现并发症,发生率为2.28%,其中3例患者出现消化道反应,2例患者出现吻合口出血, 1例患者出现吻合口瘘。术后3 d复查血常规及肝肾功能,以血小板减少、肝功能损害较多,发生率均为2.65%。 结论:进展期胃癌患者可采用氟尿嘧啶植入剂进行腹腔化疗,但需注意血小板减少、肝功能损害的发生。
ABSTRACT: OBJECTIVE: To investigate the effects of Fluorouracil implants on intraperitoneal chemotherapy safety of advanced gastric cancer patients. METHODS: The information of 264 patients with advanced gastric cancer were analyzed retrospectively. All patients were given Fluorouracil implants 800 mg, scattered into the mesenteric and surgical area, dose of each implantation site less than 200 mg, the distance of implantation range from incision and anastomosis more than 3 cm. All patients were given second generation cephalosporin 30 min before operation, at 3rd h during operation,1-3 d after operation. The occurrence of complications and ADR during hospitalization were observed after operation. RESULTS: After operation, 6 patients suffered from complications, with incidence of 2.28%, including 3 cases of gastrointestinal reaction, 2 cases of anastomotic bleeding and 1 case of anastomotic leakage. Routine blood test and liver and kidney function were rechecked 3 d after operation, mainly thrombocytopenia and liver function injury, with the incidence of 2.65%. CONCLUSIONS: Fluorouracil implants can be used for intraperitoneal chemotherapy of advanced gastric cancer patients. However, attention should be paid to thrombocytopenia and liver function injury.
期刊: 2017年第28卷第33期
作者: 陈秀峰,邹妤婕,陈利辉,魏珂,王帅奇,刘苗,李卫,孙浩
AUTHORS: CHEN Xiufeng,ZOU Yujie,CHEN Lihui,WEI Ke,WANG Shuaiqi,LIU Miao,LI Wei,SUN Hao
关键字: 进展期胃癌;氟尿嘧啶植入剂;腹腔化疗;毒性反应;安全性
KEYWORDS: Advanced gastric cancer; Fluorouracil implants; Intraperitoneal chemotherapy; Toxic reaction; Safety
阅读数: 673 次
本月下载数: 1 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!